Systemic treatment of non-small cell lung cancer brain metastases

In the systemic treatment of brain metastases from non-small cell lung cancer (BMF-NSCLC) chemo- and targeted therapy are used. Response rates after platinum-based chemotherapy, range from 23% to 45%. Development of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): gefitinib o...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Contemp Oncol (Pozn)
Autors principals: Cedrych, Ida, Kruczała, Maksymilian A., Walasek, Tomasz, Jakubowicz, Jerzy, Blecharz, Paweł, Reinfuss, Marian
Format: Artigo
Idioma:Inglês
Publicat: Termedia Publishing House 2016
Matèries:
Review Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5371701/
https://ncbi.nlm.nih.gov/pubmed/28373815
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5114/wo.2016.64593
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars